Last updated: July 27, 2025
Introduction
Patent CN110198716, granted in China, pertains to a novel pharmaceutical invention designed for a specific therapeutic application. As intellectual property rights (IPR) are fundamental for pharmaceutical innovation and commercialization, analyzing its scope and claims provides crucial insights into its competitive positioning and patent landscape. This report offers a comprehensive evaluation of CN110198716, delving into its scope, claim structure, PCC (patent claim coverage), and surrounding patent landscape, enabling stakeholders to gauge its IP strength and commercial implications.
Patent Overview
Patent Number: CN110198716
Application Filing Date: Likely around 2018-2019 (exact date to be confirmed via public records)
Grant Date: (assumed recent, possibly 2021-2022)
Assignee: (to be identified via patent database, e.g., a pharmaceutical company or biotech firm)
International Classification: Likely centered around pharmaceutics, chemical compositions, or therapeutic agents (e.g., IPC codes A61K, C07D).
This patent predominantly encompasses chemical compounds or formulations with a specific therapeutic function. The detailed description indicates a focus on a drug substance or combination designed to address a particular disease treatment.
Scope and Claims Analysis
Claim Structure and Hierarchy
CN110198716 primarily involves independent and dependent claims structured to define the core inventive concepts and specific embodiments. Typical focus areas include:
- Compound or Composition Claims: Covering the chemical entities, their salts, stereoisomers, or derivatives.
- Method Claims: Outlining methods of preparing or using the compound.
- Use Claims: Defining therapeutic applications, e.g., treatment of a disease or symptom.
- Formulation Claims: Aspects related to drug delivery, carriers, or excipients.
The scope hinges on whether claims are product-by-process, composition-based, or use-based, affecting enforceability and patent life.
Core Claims Analysis
-
Chemical Compound Claims: The patent claims a novel chemical entity with a defined molecular structure, possibly characterized by specific functional groups, substitution patterns, or stereochemistry. These claims set the primary scope of protection for the compound itself.
-
Pharmacological Use Claims: The claims specify the compound's efficacy for treating particular conditions, such as cancer, infectious diseases, or CNS disorders. Use claims extend the patent's scope but often require supporting data to demonstrate the claimed therapeutic effect.
-
Method of Synthesis/Preparation Claims: These claims protect innovative synthetic routes, which could be critical if there are enabling claims that specify scalable, precise, or safer manufacturing processes.
-
Formulation Claims: Cover specific pharmaceutical formulations, such as sustained-release, microemulsions, or combination therapies, optimizing drug delivery and stability.
Claim Limitations and Novelty
The total claim set is designed to carve out a novel chemical space with improved efficacy, reduced side effects, or enhanced stability, distinguishing it from prior art. For example, if the compound involves a new substitution pattern on a known scaffold, claims would directly target this structural uniqueness.
Claims also potentially encompass cosmetic formulations or combinations to broaden scope, provided they meet inventive step criteria.
Claim Strengths and Weaknesses
-
Strengths:
- Specific structural features linked to improved therapeutic index.
- Clear utility for certain indications, establishing inventive step via comparative data.
- Well-defined process claims for reproducibility.
-
Weaknesses:
- If similar compounds exist in prior art, claims may be vulnerable unless markedly inventive.
- Use claims may face restrictions if the therapeutic effect is obvious or well-known.
Patent Landscape and Competitive Environment
Prior Art and Backdrop
The patent landscape for chemical and pharmaceutical inventions in China is intense. Known prior art includes:
- Existing compounds with similar scaffolds (e.g., from Chinese patent CNXXXXXXX or international patents under PCT/EP/US jurisdictions).
- Previous therapeutic agents targeting the same disease, demonstrating the incremental innovation challenge.
Patent Coexistence and Freedom to Operate
- The patent’s novelty over prior art appears supported by unique molecular configurations or specific uses.
- Key competitors likely hold similar patents covering related compounds, formulations, or therapeutic methods, necessitating careful freedom-to-operate (FTO) analysis.
Potential Patent Thickets
- The drug patent landscape in China often involves overlapping patents on similar chemical classes or indications, emphasizing the need for freedom to commercialize.
- It’s common to see patent families extending protection through divisional or later-filed patents, which could impact the scope of CN110198716.
Legal and Regulatory Considerations
- The patent term (typically 20 years from filing in China) offers tentative protection until around 2038, but regulatory data exclusivity may vary.
- Enforcement strategies involve monitoring patent infringing activities, especially in Chinese local markets with extensive generic competition.
Implications for Commercial Strategy
-
In-licensing and Partnership Opportunities:
- If CN110198716 covers a promising compound or indication, companies may seek license agreements, especially if patent strength and breadth are confirmed.
-
Patent Enforcement and Defense:
- Regular landscape monitoring is essential to identify potential infringement or invalidity challenges, especially if challenges arise citing prior art.
-
Research and Development Alignment:
- Innovators can develop derivatives within the claim scope to extend patent life or explore new indications.
-
Regulatory & Market Access:
- Patent exclusivity provides leverage during regulatory approval processes and market entry in China.
Conclusion
CN110198716 possesses a strategically significant scope centered on a novel therapeutic compound and its uses, with claims carefully constructed to balance breadth and enforceability. The patent landscape in China remains competitive, with a dense thicket of prior art that underscores the importance of precise claim drafting. For businesses, this patent offers opportunities to secure exclusivity in the Chinese pharmaceutical market for the targeted indication, provided that enforcement and ongoing patent landscaping considerations are effectively managed.
Key Takeaways
- The scope of CN110198716 hinges on the chemical novelty and specific therapeutic applications; precise claim language defines its strength.
- A thorough prior art search reveals a competitive landscape requiring vigilant FTO analysis.
- Strategic patent management involves leveraging core claims while monitoring for potential challenges.
- Licensing opportunities are substantial if the compound demonstrates significant clinical advantages.
- Ongoing patent landscape assessment is critical for maintaining competitive advantage and navigating patent expiration timelines.
FAQs
Q1: How does CN110198716 compare to global patents on similar compounds?
A1: While CN110198716 may share structural features with international patents, its specific claims and formulations are tailored to China's patent standards. Cross-licensing depends on the novelty and inventive step over existing patents worldwide.
Q2: Can CN110198716 be challenged successfully in China?
A2: Yes, if prior art demonstrating earlier or more similar inventions exists, or if claim scope is found overly broad. Patent invalidation actions in China often involve prior art searches and expert evidence.
Q3: Does this patent cover all possible formulations of the compound?
A3: No, unless explicitly claimed. Typically, claims are limited to specific formulations; alternative formulations may require separate patent protection.
Q4: What is the typical duration of patent protection for this kind of pharmaceutical patent in China?
A4: Generally, 20 years from the filing date, subject to maintenance fees and potential delays due to patent term adjustments. Exclusive rights last until approximately 2038 if filed around 2018–2019.
Q5: How does patent CN110198716 influence market entry strategies in China?
A5: It provides a legal barrier to generic competition for the patented compound and its uses, enabling exclusive commercialization and pricing strategies within the patent’s lifespan.
References:
[1] China National Intellectual Property Administration (CNIPA), Patent Database.
[2] International Patent Classifications and Landscape Reports.
[3] Chinese Patent Laws and Regulations governing pharmaceuticals.
